Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | HTR1D | P28221 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | CTSK | P43235 | 1/20 | 0.67 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756457 | 1.00 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL318663 | 0.89 | SLC6A4 (0.63) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL4985934 | 0.87 | HTR2A (0.77) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL10577333 | 0.87 | SLC6A4 (0.61) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL5513682 | 0.84 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL5020054 | 0.83 | MEN1 (0.69) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7005718 | 0.83 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7004146 | 0.83 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7889427 | 0.82 | HTR2A (0.69) | HTR2ACYP3A4HTR2CHTR6MPO | |
| SCHEMBL7004071 | 0.82 | HTR2A (0.69) | HTR2ACYP3A4HTR2CHTR6MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-114716296-A | Efficient halogenation synthesis method of alkyl halide | 北京大学 | 2022-07-08 | — | — | CN | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| CN-108440373-B | Iron-catalyzed cyanoalkylindoline and preparation method thereof | 昆明学院 | 2021-05-14 | — | — | CN | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20210009603-A1 | SUBSTITUTED TETRAHYDROPYRANOINDOLES, DERIVATIVES THEREOF, AND THEIR METHODS OF SYNTHESIS AND USE | NORTHWESTERN UNIVERSITY (US) | 2021-01-14 | — | — | US | disclosed |
| WO-2017197488-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017082924-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017070026-A1 | CORROSION INHIBITION | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017049383-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2013033602-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | MILNE JILL C (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2009006089-A2 | A2 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | HTR2A 4881/4885CYP3A4 1363/4885HTR2C 4884/4885 |
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | HTR2A 3621/4885CYP3A4 4668/4885HTR2C 4341/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | HTR2A 4876/4885CYP3A4 1503/4885HTR2C 4875/4885 |
| US-20210009603-A1 | SUBSTITUTED TETRAHYDROPYRANOINDOLES, DERIVATIVES THEREOF, AND THEIR METHODS OF SYNTHESIS AND USE | HPGDS, SYVN1, PTGIS | HTR2A 488/4885CYP3A4 1833/4885HTR2C 478/4885 |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | HTR2A 4756/4885CYP3A4 2242/4885HTR2C 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.